The Respiratory area forms part of the "Providing High Quality Care" domain. It aims to increase the use of Inhaled Corticosteroids (ICS) for asthma patients in order to support effective self-management and reduce unnecessary SABA use. 

RESP-01 - this indicator looks at increasing the number of patients on Inhaled Corticosteroids (ICS). Personalised care adjustments (PCA or otherwise known as exceptions) can be applied for patients unsuitable.


RESP-02 - this indicator looks at decreasing the number of issues of Short Acting Beta-2 Agonist (SABA).


NB - patients with both Asthma and COPD will be excluded from this indicator. 


RESP-01 - Percentage of patients on the QOF Asthma Register who received three or more inhaled corticosteroid (ICS, inclusive of ICS/LABA) prescriptions over the previous 12 months31LT - 71%
UT - 90%
RESP-02 - Percentage of patients on the QOF Asthma Register who received six or more Short Acting Beta-2 Agonist (SABA) inhaler prescriptions over the previous 12 months22LT - 25%
UT - 15%

Monitoring Network DES Activity for Respiratory 

Navigate to the Population Reporting module > Ardens Searches > 5.3 Ardens National Cntrct Reports > Network Contract DES (NCD) > a. Investment and Impact Fund (IIF) > 1. Work Done > Respiratory:

If you require any further assistance on the process above, please contact Ardens support on: